VxP Biologics is a new company that provides contract development and cGMP manufacturing of biologics at its facilities in the U.S., as well as at its cGMP facility in India. All VxP facilities are U.S.-FDA audited and are currently serving the global pharmaceutical and biotech industry.

VxP Biologics will offer process development and manufacturing of biologics, including recombinant DNA engineering, cell line development, protein sciences (purification and crystallography), in-vivo pharmacology, toxicology, as well as cGMP antibody generation.
The new company was formed by VxP Pharma, which began operations in 2010 as CRO Solutions, a sales representation agency representing global contract research organizations (CROs) and contract manufacturing organizations (CMOs) from a business development and marketing standpoint. VxP Pharma was launched in 2014 as a platform to promote the combined services of all CRO Solutions clients under a single brand. VxP offers its services to research and development scientists at pharma and biotech companies worldwide.

“The VxP Pharma platform has been extremely successful both for us, and for our global clients,” said Raymond Peck, chief executive officer, VxP Pharma. “Biologics has become a growing part of our portfolio, so we feel that the creation of VxP Biologics is a natural extension of our service offering, and of our VxP brand.”

VxP is headquartered in Indianapolis, IN.